| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/04/2006 | US20060094680 Modified with glycerol, arabinoguanosine, and a phosphodiester linkage; self-complementary; antiinflammatory, anticarcinogenic, antihistamine, antiallergen, and bronchodilator agents; autoimmune and skin disorders |
| 05/04/2006 | US20060094677 Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics |
| 05/04/2006 | US20060094676 Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| 05/04/2006 | US20060094674 Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| 05/04/2006 | US20060094672 Mimetic amino acid sequences for use in prevention and treatment of cell proliferative disorders |
| 05/04/2006 | US20060094671 With (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate; immunomodulators; nucleosides |
| 05/04/2006 | US20060094670 Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| 05/04/2006 | US20060094669 Salts of lipophilic acids, such as fatty acids, diacids, polycarboxylic acids and aromatic acids in a pharmaceutically acceptable solvent to form an injectable composition that precipitates when injected into water; improved pharmacokinetics |
| 05/04/2006 | US20060094668 Coadministration of tigecycline and digoxin |
| 05/04/2006 | US20060094667 e.g. 1,2-Dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one; human SGLT2 (sodium ion / glucose cotransporter 2) inhibitors; antidiabetic and hyperglycemic agents; obesity; synergistic mixture with other active compounds |
| 05/04/2006 | US20060094666 Water-soluble chitosan-indole-3-propionic acid conjugates |
| 05/04/2006 | US20060094664 Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation |
| 05/04/2006 | US20060094660 Inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer |
| 05/04/2006 | US20060094654 Neuroprotective complex for treatment of cerebral ischemia and injury |
| 05/04/2006 | US20060094651 Formulations and methods of production of FGF-20 |
| 05/04/2006 | US20060094645 Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (TFNalpha), interleukin-1 (lL-1), and interleulin-6R(lL-6R) antagonists |
| 05/04/2006 | US20060094643 Compositions of hyaluronic acid and methods of use |
| 05/04/2006 | US20060094608 Mixture of polyol and insulation agent; heating upon exposure to moisture; for urogenital systems; dysmenorrhea |
| 05/04/2006 | US20060094082 Induces modulation of immune system whereby composition stimulates production of macrophage inflammatory protein-3 alpha from hepatoctyes; use in treating hyperproliferative disease, respiratory disorders, cardiovascular disease, neurological conditions, autoimmune, infectious, gastrointestinal disorders |
| 05/04/2006 | US20060094079 Protein for blocking platelet adhesion |
| 05/04/2006 | US20060094075 Methods for indentifying compounds that modulate an enzyme in the coenzyme a biosynthetic pathway in a pathogenic microoganism |
| 05/04/2006 | US20060094068 Predictive markers in cancer therapy |
| 05/04/2006 | US20060094063 fenretinide derivatives; dry forms of age-related macular degeneration and dystrophies, geographic atrophy; complex may be detected by fluorescence resonance energy transfer |
| 05/04/2006 | US20060094043 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 05/04/2006 | US20060094032 iRNA agents targeting VEGF |
| 05/04/2006 | US20060094021 Drug screening; predicting differential chemosensitivity and tailoring chemotherapy in non small cell lung carcinoma (NSCLC) |
| 05/04/2006 | US20060094013 Salt-inducible kinases 2 and use thereof |
| 05/04/2006 | US20060094012 Polymorphisms for predicting disease and treatment outcome |
| 05/04/2006 | US20060093688 Nutritional olive oil based compositions, and method of consumption thereof |
| 05/04/2006 | US20060093687 Administering N-(2-bromophenyl)-N'-[((R)-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)]urea and rofecoxib |
| 05/04/2006 | US20060093683 Stable cleanser compositions containing sulfur |
| 05/04/2006 | US20060093682 Stable cleanser compositions containing sulfur |
| 05/04/2006 | US20060093680 Coated particles and pharmaceutical dosage forms |
| 05/04/2006 | US20060093679 Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve |
| 05/04/2006 | US20060093676 Ascorbic acid stability |
| 05/04/2006 | US20060093675 Intravaginal treatment of vaginal infections with metronidazole compositions |
| 05/04/2006 | US20060093671 Galantamine particles that may be in salt form and an excipient, coated by a release rate controlling membrane; alleviates Alzheimer's dementia and related dementias, when used in amounts insufficient to cause adverse effects |
| 05/04/2006 | US20060093670 Sustained-release composition process for producing the same and preparation thereof |
| 05/04/2006 | US20060093668 Melt granulated composition and modified release dosage form prepared from said composition |
| 05/04/2006 | US20060093667 Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency |
| 05/04/2006 | US20060093666 Formulations for tyrosine kinase inhibitors |
| 05/04/2006 | US20060093665 Method to improve surface properties of pharmaceutical tablets |
| 05/04/2006 | US20060093664 soft gelatin capsule comprising alpha-, beta-, delta-, and gamma-forms of tocopherols and tocotrienols; to provide protection of the cell membrane lipid layer, and protection against heart disease, cancer, and eye disease |
| 05/04/2006 | US20060093662 Liposomal camptothecins and uses thereof |
| 05/04/2006 | US20060093659 Hydroxide-releasing agents as skin permeation enhancers |
| 05/04/2006 | US20060093656 Warming patch |
| 05/04/2006 | US20060093651 Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
| 05/04/2006 | US20060093650 Methods for regulating weight and size of animals |
| 05/04/2006 | US20060093647 Multiple layer coating composition |
| 05/04/2006 | US20060093643 Medical device for delivering therapeutic agents over different time periods |
| 05/04/2006 | US20060093636 Allantoin-containing skin cream |
| 05/04/2006 | US20060093633 Cosmetic and/or dermatological preparation comprising 2,3-dibenzylbutyrolactones |
| 05/04/2006 | US20060093632 Compositions for controlled delivery of pharmaceutically active compounds |
| 05/04/2006 | US20060093604 Method of treatment and prophylaxis |
| 05/04/2006 | US20060093602 Inflammatory mediator antagonists |
| 05/04/2006 | US20060093600 Antibodies to CD40 |
| 05/04/2006 | US20060093598 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093597 Methods of treating involuntary facial spasms and facial wrinkles |
| 05/04/2006 | US20060093595 Methods, compositions and kits for treating damage to excitable tissue |
| 05/04/2006 | US20060093592 Synbiotics |
| 05/04/2006 | US20060093585 Providing mammalian cell contacted with agent and adeno-associated virus (AAV), identifying agent that when contacted with mammalian cell enhances AAV transduction after viral binding to membrane of contacted mammalian cell and before second strand synthesis which yields expressible form of viral genome |
| 05/04/2006 | US20060093580 Tolerogenic vaccine and method |
| 05/04/2006 | US20060093578 Method and composition for treating multiple sclerosis |
| 05/04/2006 | US20060093577 Combination anti-viral compositions and methods of use |
| 05/04/2006 | US20060093576 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093575 Oxaliplatin anti-resistance agent |
| 05/04/2006 | US20060093573 Drug composition with antimicrobial activity |
| 05/04/2006 | US20060093572 Cyanoacrylate monomer formulation containing diiodomethyl-p-tolylsulfone and 2,4,4'-trichloro-2' -hydroxydiphenyl ether |
| 05/04/2006 | US20060093570 Surface treatment |
| 05/04/2006 | US20060093567 Method of inhibiting hair growth |
| 05/04/2006 | US20060093561 Method of treating microorganisms in the oral cavity |
| 05/04/2006 | US20060093557 Particulate composition |
| 05/04/2006 | US20060093553 Cd26-based therapies for cancers and immune disease |
| 05/04/2006 | DE19954788B4 Neue pharmazeutische Verwendung von Mibefradil in der chirurgischen Ophthalmologie New pharmaceutical use of mibefradil in surgical ophthalmology |
| 05/04/2006 | DE102004052877A1 Stabile wässrige Formulierungen eines Platin Derivats A stable aqueous formulations of a platinum derivative |
| 05/04/2006 | CA2730374A1 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| 05/04/2006 | CA2589324A1 Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal |
| 05/04/2006 | CA2588350A1 Anti-mitotic anti-proliferative compounds |
| 05/04/2006 | CA2587026A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| 05/04/2006 | CA2586738A1 (2-carboxamido)(3-amino) thiophene compounds |
| 05/04/2006 | CA2586681A1 Compositions for treating and/or preventing diseases characterized by the presence of the metal ions |
| 05/04/2006 | CA2586040A1 Sustained release of active molecules from polymers topically applied to skin or hair |
| 05/04/2006 | CA2585970A1 Mammalian genes involved in infection |
| 05/04/2006 | CA2585836A1 Process for forming amorphous atorvastatin |
| 05/04/2006 | CA2585711A1 Conjugates with anti-inflammatory activity |
| 05/04/2006 | CA2585642A1 Carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof |
| 05/04/2006 | CA2585638A1 Aminopyridine derivatives having aurora a selective inhibitory action |
| 05/04/2006 | CA2585418A1 4-aminotetracyclines and methods of use thereof |
| 05/04/2006 | CA2585367A1 Therapeutic and delivery methods of prostaglandin ep4 agonists |
| 05/04/2006 | CA2585353A1 Phosphonate derivatives of mycophenolic acid |
| 05/04/2006 | CA2585340A1 Compositions and methods of dispensing palliative or therapeutic agents |
| 05/04/2006 | CA2585293A1 Lip enhancement compositions |
| 05/04/2006 | CA2585281A1 Phosphonate substituted kinase inhibitors |
| 05/04/2006 | CA2585268A1 Methods for lowering hif-1 mediated gene expression |
| 05/04/2006 | CA2585248A1 Substituted tetracycline compounds |
| 05/04/2006 | CA2585177A1 Aryl sulfonic pyridoxines as antiplatelet agents |
| 05/04/2006 | CA2585175A1 Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
| 05/04/2006 | CA2585174A1 Substituted pyridoxines as anti-platelet agents |
| 05/04/2006 | CA2585170A1 4-methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors |
| 05/04/2006 | CA2585138A1 Process for the preparation of irbesartan hydrochloride |